Date: 2013-05-13
Type of information: Fundraising
Company: Neovacs (France)
Investors: OSEO (France)
Amount: €414,839
Funding type:
Planned used: This payment supports Tracker, a development project with its TNF-Kinoid drug candidate for rheumatoid arthritis.
Others:
Last November, Neovacs has presented Month 6 follow–up results of its TNF–Kinoid Phase II study in rheumatoid arthritis in a poster during the Annual Meeting of the American College of Rheumatology on November 11, 2012 in Washington,DC. A phase 2b study of TNF-Kinoid in rheumatoid arthritis is now expected to start in mid 2013.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases